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Abstract
Background: Glucocorticoids are an important class of medication for patients with adult-onset Still disease (AOSD), however,
relapse following glucocorticoid reduction and adverse events due to long-term effects of glucocorticoid are still problematic. It is of
course essential to minimize the risk of treatment. Immunosuppressive therapies such as methotrexate and biologics including
tocilizumab are used in glucocorticoid-dependent patients with AOSD, but no second-line treatments for patients with glucocorticoid
dependence have been established yet. Given that these drugs also have the potential to cause adverse events, alternative
treatments are sought. Recently, elevated heme oxygenase-1 (HO-1) has been reported in the serum of patients with AOSD,
suggesting that HO-1 activity contributes to AOSD pathogenesis and may represent a new therapeutic target for the treatment of
AOSD. The amino acid 5-aminolevulinic acid (5-ALA) is a non-proteinogenic d amino acid in human body. An addition of ferrous iron
to 5-ALA enhances heme biosynthesis. The increase in heme in vivo induces HO-1 production, a heme-degrading enzyme. Elevated
HO-1 has been suggested to contribute to the pathogenesis of AOSD, and administration of 5-ALA and ferrous iron may be a
potential treatment for AOSD.
Methods/design: This study is a single-arm, open-label pilot intervention study using clinical endpoints to investigate the effects
of oral 5-ALA with sodium ferrous citrate on glucocorticoid reduction in patients with AOSD receiving glucocorticoid therapy.
Discussion: This pilot intervention study will provide evidence regarding the effectiveness and safety of 5-ALA/sodium ferrous
citrate as a potential new therapeutic agent for glucocorticoid-dependent patients with AOSD.
Trial registration: This study was registered in the Japan Registry of Clinical Trials (https://jrct.niph.go.jp) on January 14, 2020 as
jRCTs071190042.
The trial received ethical approval on December 25, 2019. Recruitment started in January 2020 and the trial is expected to finish December 31, 2021.
The study protocol has been approved by the certified review board of Nagasaki University. The reference number is CRB19-017. Written informed consent will be
provided by patients before enrollment.
Results obtained in this trial will be published in an international journal and may be presented at international scientific meetings. This will be included in the patient
consent form.
The investigational drug (5-ALA/SFC) was provided by Neopharma Japan Co., Ltd.
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Abbreviations: 5-ALA = 5-aminolevulinic acid, AOSD = adult-onset Still disease, CRB = certified review board, CRF = case
report form, HO-1 = heme oxygenase-1, IL = interleukin, PSL = prednisolone, SFC = sodium ferrous citrate, SPIRIT = Standard
Protocol Items: Recommendations for Interventional Trials.
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1. Introduction
Adult-onset Still disease (AOSD) is a systemic inflammatory
disorder of unknown etiology, characterized by fever, joint
symptoms, and skin rash.[1] Initial treatment for patients with
moderate to severe disease activity is systemic administration of
moderate to high doses of glucocorticoids, however, response
varies among patients. Furthermore, cases exist of patients
becoming resistant to glucocorticoids and who relapse during
tapering of doses. Adverse events such as organ damage and
infection associated with long-term administration may be a
problem for patients treated with glucocorticoid alone. In such
cases, combination therapy with tocilizumab, methotrexate, and/
or cyclosporine is an option. Clinical practice guidelines for adult
Still disease in Japan[2] include recommendations for these
treatments, but evidence regarding safety and efficacy is scarce,
and treatments are still under development.
Although AOSD pathogenesis remains unclear, elevated heme
oxygenase-1 (HO-1) has recently been reported in the serum of
patients with AOSD. Moreover, its expression decreases
following treatment in parallel with serum ferritin levels, which
are conventionally used as a marker of disease activity in
AOSD.[3] This finding suggests that HO-1 activity contributes to
AOSD pathogenesis.
The amino acid 5-aminolevulinic acid (5-ALA), a non-
proteinogenic d amino acid found in the human body, promotes
intracellular energy metabolism, and addition of ferrous iron to 5-
ALA enhances heme biosynthesis. The increase in heme in vivo
inducesHO-1production, a heme-degrading enzyme. The increase
in heme also induces NF-E2 related factor (Nrf-2) expression,
upstream of HO-1, and its downstream anti-inflammatory
cytokines, which exert immune tolerance and anti-inflammatory
effects.[4] It has been suggested that elevatedHO-1 in patients with
AOSD results from an excessive immune response. Therefore, oral
5-ALAwith sodium ferrous citrate (SFC)may be effective inAOSD
treatment, exerting immune tolerance, and anti-inflammatory
effects via induction of HO-1 production.
We hypothesized that additional 5-ALA/SFC administration in
patients with AOSD may improve disease activity and allow for
glucocorticoid reduction. We; therefore, designed this study as
the first step in validating the effectiveness of 5-ALA/SFC in the
treatment of AOSD. Herein, we describe the final study protocol
(version 1.4; May 19, 2020). The results of this study are
expected to provide evidence on the usefulness of 5-ALA/SFC in
the treatment of glucocorticoid-dependent patients with AOSD.
2. Methods/design
2.1. Study design
The present study design is in accordance with Standard Protocol
Items: Recommendations for Interventional Trials and Consoli-
dated Standards of Reporting Trials 2010 guidelines.[5,6] This is a
single-arm, open-label, pilot intervention study to investigate the
effects of 5-ALA/SFC on glucocorticoid reduction in patients with
AOSD.
The study will be conducted at 2 centers in Japan. In total, 7
patients with AOSDwill be recruited to the study, with a 16 week
duration of intervention. The study has been approved by the
certified review board (CRB) of Nagasaki University (CRB
approval no.: CRB19-017) and is registered in the Japan Registry
of Clinical Trials (https://jrct.niph.go.jp) as jRCTs071190042.
The study will be conducted in accordance with the principles of
the Declaration of Helsinki,[7] the Clinical Trials Act (Act No. 16
of April 14, 2017), the Act on the Protection of Personal
Information and related regulatory notifications, and the present
study protocol.
2.2. Participant recruitment
Participants will be recruited at the Nagasaki University Hospital
and Nagasaki Genbaku Hospital. The study will be explained to
participants by their attending rheumatologist; participants will
then be asked to voluntarily sign an informed consent form before
their participation.
2.3. Inclusion criteria
Inclusion criteria are as follows:
(1) Patients aged 20 years or older at the time of consent.
(2) Patients undergoing treatment in an outpatient setting.
(3) Patients diagnosed with AOSD according to Yamaguchi
criteria.[8]
(4) Patients treated with oral prednisolone (PSL) at a dose of
between 5mg/d and 30mg/d.
(5) Patients who continued the same dose of oral PSL for at least
8 weeks before 5-ALA/SFC administration.
(6) Patients who have not received a change in dose or any new
treatment for AOSD for at least 8 weeks before 5-ALA/SFC
administration.
(7) Patients who are willing and able to give written informed
consent and comply with requirements of the study protocol.
2.4. Exclusion criteria
Exclusion criteria are as follows:
(1) Patients classified as severe according to the AOSD severity
classification of the Research Team for Autoimmune
Diseases, the Research Program for Intractable Disease of
the Ministry of Health, Labor and Welfare, Japan.[9]
(2) Patients who have previously taken 5-ALA/SFC.
(3) Patients who cannot use appropriate contraception during
the drug administration period of the study.
(4) Female patients during pregnancy or lactation.
(5) Patients judged inappropriate for any other reason by the
clinical investigator or clinical trial physician.
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2.5. Study protocol
AOSD patients who have received a consistent dose of PSL for at
least 8 weeks will be administered an additional daily 200mg of
5-ALA/SFC for 16 weeks. At weeks 4 and 10 after the start of
study, the oral PSL dose will be reduced according to the
prescribed protocol to determine whether relapse or exacerbation
occur. A physician will explain the study protocol to each patient
and, if consent is obtained, the physician will perform the
observation/examination at the time of registration in keeping
with the description in Figure 1. According to the inclusion and
exclusion criteria, the physician will fax the participant
registration form to the registration center.
After the visit date, the physician will continue to administer 5-
ALA/SFC and conduct necessary examinations and surveys until
week 16 in accordance with the schedule in Figure 1. The
protocol for PSL reduction is as follows, depending on PSL dose
at the time of visit.
1. For 15mg < PSL  30mg/day: 8% to 12% dose reduction.
2. 7.5 < PSL  15mg/d: 1mg/d dose reduction.
3. For PSL  7.5mg/d: 0.5mg/d dose reduction.
For example, a patient taking PSL 8mg/d at the start of
the study should be reduced to 7mg/d at week 4 and 6.5mg/d at
week 10.
During the study period, new initiation of the following
treatments is prohibited: the administration of immunosuppres-
sants, biologics or Janus kinase inhibitors, intra-articular
corticosteroid injections at joints, and oral nonsteroidal anti-
inflammatory drug and suppositories.
A patient may be discontinued prematurely for the following
reasons (patients who discontinue before completing the trial will
not be replaced):
 The patient asks to leave the trial.
 Continuing participation is inadvisable due to adverse event(s).
Figure 1. Treatment schedule and outcome measures. CRP = C reactive protein, ESR = erythrocyte sedimentation rate, VAS = visual analog scale.
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 5-ALA/SFC must be withdrawn more than 4 weeks for some
reason(s).
 5-ALA/SFC must be reduced more than half the daily dose for
some reason(s).
 In the physician’s opinion, continuation in the trial would be
detrimental to the patient’s well-being.
2.6. Adverse events
A serious adverse event is defined as any untoward medical event
that occurs at any dose, results in death, is life-threatening,
requires inpatient hospitalization or prolongation of existing
hospitalization, results in persistent or significant disability or
incapacity, or causes a congenital anomaly or birth defect.
All serious adverse events occurring between the signing of
informed consent and the end of the trial will be documented in
the medical records and reported to the CRB by the responsible
investigator in accordance with Japanese regulations.
2.7. Study endpoints
2.7.1. Primary endpoint. The primary endpoint is the propor-
tion of patients who were able to maintain PSL reduction without
relapse or exacerbation after study initiation.
2.7.2. Secondary endpoints. The secondary endpoints are as
follows:
(1) Clinical signs (fever, joint symptoms, rash, and lymph node
enlargement): change from baseline at 4, 10, and 16 weeks,
and at the time of drug discontinuation.
(2) Abnormalities in laboratory tests based on the systemic
feature score[10,11] (white blood cells [/μL], hemoglobin [g/dL],
platelet [/μL], C reactive protein [mg/dL], and erythrocyte
sedimentation rate [mm/h]): change frombaseline at 4, 10, and
16 weeks, and at the time of drug discontinuation.
(3) Changes from baseline systemic feature score at 4, 10, and 16
weeks, and at the time of drug discontinuation.
(4) Physician global assessment (disease activity assessment, 100
mm visual analog scale): changes from baseline at 4, 10, and
16 weeks, and at the time of drug discontinuation.
(5) Patient global assessment (disease activity assessment, 100
mm visual analog scale): changes from baseline at 4, 10, and
16 weeks, and at the time of drug discontinuation.
(6) Serum ferritin levels: changes from baseline at 4, 10, and 16
weeks, and at the time of drug discontinuation.
2.8. Data collection and management
Appropriate and authorized persons (investigators, physicians,
and collaborators) will prepare a case report form (CRF). All data
recorded in the CRF must be consistent with original material
unless data recorded directly in the CRF are used as the source
material. The investigator will collect data at each visit during the
study, in accordance with the schedule in Figure 1. All study
findings and documents will be made confidential and patients
will always be identified by their patient number and/or birth
date, never by name. Confidentiality patient-identifying docu-
ments will be maintained by the investigator to preserve
participant anonymity.
During the study, a sponsor-investigator will undertake regular
site visits to review protocol compliance, conduct source data
verification, assess drug accountability and management and
assess laboratory procedures to ensure that the study is being
conducted according to all pertinent requirements.
2.9. Statistical analysis
The population to be analyzed is defined as all subjects receiving
at least 1 dose of 5-ALA/SFC throughout the study. Character-
istics of all 5-ALA/SFC-treated populations will be summarized
using descriptive statistics. Effectiveness endpoint listed in 2.7
will be estimated point estimates and 95% confidence intervals.
Safety and tolerability analyses will be based on this analysis set.
Adverse events will be stratified by serious vs. nonserious, causal
relationship, severity, outcome, and presence or absence of
clinical relapse. Analyses will be categorized and tabulated by
name and a list will be formulated, including causality, extent,
and outcomes.
Data relevant to this clinical trial will be analyzed using R
software version 4.0.0 or higher, or JMP Pro 15 or higher.
3. Discussion
AOSD is a systemic inflammatory disorder. Autoantibodies such
as antinuclear antibodies are generally not detected, however, it is
thought that hypercytokinemia involving interleukin-1b (IL-1b),
IL-6, IL-18, and tumor necrosis factor-a, due to abnormal
activation of innate immune cells such as monocytes and
macrophages, may be involved in disease pathogenesis.[12] The
clinical course of AOSD is divided into 3 types: monophasic,
intermittent, and chronic.[13–15] Long-term treatment is particu-
larly essential in intermittent and chronic types in which systemic
symptoms relapse repeatedly. As mentioned previously, there is
still no established, well-evidenced treatment for AOSD.
Treatment options consist of glucocorticoids, biologics, and
immunosuppressive drugs, but adverse events and concomitant
infections associated with long-term medication can be problem-
atic. Treatment options with different mechanisms of action from
those above are therefore sought to solve these problems.
HO-1, also known as heat shock protein-32, is a 32kD heme-
degrading enzyme[16] inducedbyvarious stresseswhich is reportedly
increased in the serum of patients with adult-onset Still disease.
Heterodimers of Nrf-2 and small Maf, transferred from the
cytoplasm to the nucleus by stress, bind to antioxidant responsive
elements and induce the transcriptionof antioxidants includingHO-
1and ferritin.[17] InductionofHO-1production is thought to elevate
expression of regulatory dendritic cells, induce regulatory T-cell
differentiation and immune tolerance, promote M2 macrophage
differentiation and exert anti-inflammatory effects.[18]
The addition of divalent iron to 5-ALA enhances heme
biosynthesis.[18] In vivo increases in heme induce HO-1
production, which is a heme-degrading enzyme. These increases
also induce Nrf-2, upstream of HO-1, and its downstream anti-
inflammatory cytokines, which exert immune tolerance and anti-
inflammatory effects. Oral administration of 5-ALA/SFC may be
an effective treatment for AOSD via the immune tolerizing and
anti-inflammatory effects of HO-1.
In the present study, we will administer 5-ALA/SFC to
glucocorticoid-dependent patients with AOSD, and determine
whether PSL reduction can be maintained without relapse or
exacerbation after study initiation. There are no restrictions on
concomitant use of immunosuppressive drugs or biologics, and
this is a pilot study examining the steroid reduction effect of
addition of 5-ALA/SFC to standard treatment.
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In our study, we will use the systemic feature score as a
secondary endpoint to determine clinical effectiveness of 5-ALA/
SFC. This scoring system, consisting of 5 clinical and 5 laboratory
assessments, was designed to evaluate systemic disease fea-
tures.[10] It was also previously used as a secondary endpoint in a
phase III trial on the efficacy of tocilizumab in Japanese patients
with AOSD.[11] Because the present study excludes patients
receiving high dose of glucocorticoids and patients with severe
AOSD, the systemic feature score at baseline is expected to be
low. As this score is likely to be elevated at the time of relapse, we
considered this score be a reasonable endpoint for determining
relapse.
The dosage of the investigational drug will be set at 100mg
orally twice daily (200mg/d) in accordance with a previous study
conducted in patients with type 2 diabetes (ClinicalTrials.gov
NCT02481141),[19] which demonstrated the safety and tolera-
bility of such a dose.[19] We consider that this dose is acceptable
and effective for patients with AOSD.
This trial will evaluate the effectiveness and safety of 5-ALA/
SFC in glucocorticoid-dependent patients with AOSD. It will
support the potential effectiveness of 5-ALA/SFC in preventing
relapse or exacerbation after the reduction of glucocorticoid and
in improving patient quality of life and vital prognosis. The
findings of this study are expected to provide new treatment
options for AOSD.
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